Latest BioSpecifics Technologies Corp. Stories
LYNBROOK, N.Y., July 12 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that its strategic partner Auxilium Pharmaceuticals, Inc. has provided an update on XIAFLEX, its injectable collagenase product currently marketed in the U.S. for the treatment of Dupuytren's contracture. Auxilium announced that XIAFLEX sales to physicians were $2.0 million for the second quarter...
LYNBROOK, N.Y., June 2 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Jefferies & Company 2010 Global Life Sciences Conference on Wednesday, June 9, 2010, at 2:30pm EDT. A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the...
LYNBROOK, N.Y., May 7 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC; the "Company"), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the first quarter ended March 31, 2010. The Company also highlighted key commercial and regulatory progress during the quarter, and provided its expected milestones for the remainder of 2010. "The first quarter of 2010 was a very exciting time here at...
LYNBROOK, N.Y., May 3 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 8:30am EDT on Friday, May 7, 2010 to report its first quarter 2010 financial results and corporate highlights. To participate in the call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The live webcast can be...
LYNBROOK, N.Y., March 25 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC, the "Company"), a biopharmaceutical company developing first in class collagenase-based products, today announced that the Company's Board of Directors has scheduled its Annual Meeting of Stockholders ("Meeting") to be held on Thursday, June 17, 2010 at 11:00 a.m. Eastern Daylight Time in New York City. Stockholders of record as of the close of business on April 19, 2010 will be entitled to...
LYNBROOK, N.Y., March 10 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended December 31, 2009. "2009 was a great year for XIAFLEX, highlighted by the recent FDA approval for the treatment of Dupuytren's contracture and its commercial availability on March 8th. We believe the drug has strong market...
LYNBROOK, N.Y., March 8 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that XIAFLEX(TM) is now available in the U.S. by prescription, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen deposition that causes contractures of the fingers. "We're excited...
LYNBROOK, N.Y., March 5 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 4:30pm ET on Wednesday, March 10, 2010 to report its fourth quarter and full year 2009 financial results and corporate highlights. To participate in the call, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The live...
LYNBROOK, N.Y., March 1 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming Cowen and Company 30th Annual Health Care Conference on Monday, March 8, 2010, at 3:15pm ET at the Boston Marriott Copley Place in Boston, Massachusetts. A live webcast of the presentation can be accessed under "Calendar of...
LYNBROOK, N.Y., Feb. 2 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that the U.S. Food and Drug Administration (FDA) has approved XIAFLEX(TM), a novel, first-in-class, orphan-designated, biologic, for the treatment of adult Dupuytren's contracture patients with a palpable cord. Dupuytren's contracture is a debilitating disease resulting from excessive collagen...
